Non-pegylated interferon beta drugs were approved in the mid 1990s (EMA) for the treatment of relapsing MS (SC interferon beta-1b, 1995; intramuscular (IM) interferon beta-1a, 1997; SC interferon beta-1a, 1998). Here, IFNB1 is linked to myeloid sarcoma.